NDAORALCAPSULE, TABLETPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA DUAL PAK is a fixed-dose combination of vonoprazan fumarate (a potassium-competitive acid blocker) and amoxicillin indicated for Helicobacter pylori eradication in adults. This dual-therapy oral regimen represents an advance in H. pylori treatment with improved acid suppression and antimicrobial efficacy. The product addresses a significant unmet need in infectious disease by offering a more convenient and effective alternative to traditional triple-therapy regimens.
Peak4.1 years to LOE
Product is at peak commercial maturity approximately 2.5 years post-launch, suggesting established team size with focus on market penetration and retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VOQUEZNA DUAL PAK at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.